Logo image of CTNM

CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Fundamental Analysis

NASDAQ:CTNM - Nasdaq - US21217B1008 - Common Stock - Currency: USD

6.77  +0.33 (+5.12%)

After market: 6.77 0 (0%)

Fundamental Rating

4

CTNM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. CTNM has an excellent financial health rating, but there are some minor concerns on its profitability. CTNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year CTNM was profitable.
In the past year CTNM has reported a negative cash flow from operations.
CTNM Yearly Net Income VS EBIT VS OCF VS FCFCTNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 10M -10M 20M -20M

1.2 Ratios

With an excellent Return On Assets value of 10.52%, CTNM belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
CTNM's Return On Equity of 10.81% is amongst the best of the industry. CTNM outperforms 88.54% of its industry peers.
CTNM has a Return On Invested Capital of 6.04%. This is amongst the best in the industry. CTNM outperforms 83.33% of its industry peers.
Industry RankSector Rank
ROA 10.52%
ROE 10.81%
ROIC 6.04%
ROA(3y)-23.87%
ROA(5y)N/A
ROE(3y)-30.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTNM Yearly ROA, ROE, ROICCTNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -20 -40 -60

1.3 Margins

CTNM's Profit Margin of 45.44% is amongst the best of the industry. CTNM outperforms 98.44% of its industry peers.
With an excellent Operating Margin value of 32.15%, CTNM belongs to the best of the industry, outperforming 94.79% of the companies in the same industry.
Industry RankSector Rank
OM 32.15%
PM (TTM) 45.44%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTNM Yearly Profit, Operating, Gross MarginsCTNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 10 20 30 40

More info and screens

9

2. Health

2.1 Basic Checks

CTNM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CTNM remains at a similar level compared to 1 year ago.
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTNM Yearly Shares OutstandingCTNM Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M 25M
CTNM Yearly Total Debt VS Total AssetsCTNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

CTNM has an Altman-Z score of 19.01. This indicates that CTNM is financially healthy and has little risk of bankruptcy at the moment.
CTNM's Altman-Z score of 19.01 is amongst the best of the industry. CTNM outperforms 91.67% of its industry peers.
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.01
ROIC/WACC0.64
WACC9.49%
CTNM Yearly LT Debt VS Equity VS FCFCTNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 37.06 indicates that CTNM has no problem at all paying its short term obligations.
CTNM has a Current ratio of 37.06. This is amongst the best in the industry. CTNM outperforms 98.96% of its industry peers.
A Quick Ratio of 37.06 indicates that CTNM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 37.06, CTNM belongs to the top of the industry, outperforming 98.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 37.06
Quick Ratio 37.06
CTNM Yearly Current Assets VS Current LiabilitesCTNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

CTNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 193.68%, which is quite impressive.
EPS 1Y (TTM)193.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -76.55% on average over the next years. This is quite bad
The Revenue is expected to decrease by -36.59% on average over the next years. This is quite bad
EPS Next Y-316.16%
EPS Next 2Y-100.94%
EPS Next 3Y-76.55%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-65.01%
Revenue Next 3Y-36.59%
Revenue Next 5YN/A

3.3 Evolution

CTNM Yearly Revenue VS EstimatesCTNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
CTNM Yearly EPS VS EstimatesCTNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.52 indicates a rather cheap valuation of CTNM.
94.27% of the companies in the same industry are more expensive than CTNM, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 29.35. CTNM is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for CTNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.52
Fwd PE N/A
CTNM Price Earnings VS Forward Price EarningsCTNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -13.03
CTNM Per share dataCTNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as CTNM's earnings are expected to decrease with -76.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-100.94%
EPS Next 3Y-76.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTNM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTINEUM THERAPEUTICS INC-A

NASDAQ:CTNM (3/7/2025, 8:16:37 PM)

After market: 6.77 0 (0%)

6.77

+0.33 (+5.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners75.4%
Inst Owner Change14.59%
Ins Owners6.19%
Ins Owner Change-1.27%
Market Cap174.53M
Analysts86
Price Target29.84 (340.77%)
Short Float %5.19%
Short Ratio9.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.84%
Min EPS beat(2)-10.03%
Max EPS beat(2)4.35%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.52
Fwd PE N/A
P/S 3.49
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.83
EV/EBITDA -13.03
EPS(TTM)0.9
EY13.29%
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS1.94
BVpS8.15
TBVpS8.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.52%
ROE 10.81%
ROCE 7.65%
ROIC 6.04%
ROICexc N/A
ROICexgc N/A
OM 32.15%
PM (TTM) 45.44%
GM N/A
FCFM N/A
ROA(3y)-23.87%
ROA(5y)N/A
ROE(3y)-30.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 298.64%
Cap/Sales 1.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.06
Quick Ratio 37.06
Altman-Z 19.01
F-Score6
WACC9.49%
ROIC/WACC0.64
Cap/Depr(3y)99.96%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)193.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.43%
EPS Next Y-316.16%
EPS Next 2Y-100.94%
EPS Next 3Y-76.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-65.01%
Revenue Next 3Y-36.59%
Revenue Next 5YN/A
EBIT growth 1Y170.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-394.68%
EBIT Next 3Y-98.38%
EBIT Next 5YN/A
FCF growth 1Y193.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y196.16%
OCF growth 3YN/A
OCF growth 5YN/A